Xenon.
nightclub in New York City
- Reports this week
- 1
- Active events
- 2
- Connections
- 37
What's happening
Active this week
-
Xenon and Neurocrine Biosciences announced a partnership on August 12, 2025, allowing collaboration and milestone payments regarding Azetukalner, which is Xenon's lead pipeline candidate.Some support2 reports
-
Xenon reported financial results from Vancouver and Boston and named Mortimer as its President and CEO.Well supported4 reports
One to three months ago
-
Deutsche Bank downgraded stock and Needham cut price targets citing safety concerns regarding Xenon's product ahead of its NDA meeting.Some support1 report
-
Xenon and Coya Therapeutics are both clinical-stage biotech companies.Some support1 report
-
Xenon, a company headquartered in Canada, began trading on the Nasdaq stock exchange.Some support1 report
Gone quiet
No new reports in 90+ days-
Deutsche Bank raised its price target on Biohaven Ltd. on July 6, 2026, while Biohaven trails Xenon's competing program by two years.Some support1 report
-
Xenon Pharmaceuticals maintains offices in Vancouver and Boston.Well supported9 reports
-
RBC maintained an Outperform rating on Xenon Pharmaceuticals, noting Azetukalner as its top medication candidate, while Trump-era tariffs benefit AI stocks.Speculative1 report
-
Xenon Pharmaceuticals appointed Darren Cline as Chief Commercial Officer on June 24, 2025.Speculative1 report
-
Xenon Pharmaceuticals is developing azetukalner for various conditions and has completed patient recruitment for the X-TOLE2 Phase 3 clinical trial.Some support2 reports
-
Xenon Pharmaceuticals was included in a broad-market index on June 28, 2025.Speculative1 report
No events began in the chosen period. Widen it, or reset.
Around Xenon this week
News at the entities that move Xenon most-
FDA StructuralFDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Moves Xenon
-
Deutsche Bank TransactionalDeutsche Bank cut its rating on RTX stock to hold on November 11, 2026.Moves Xenon
-
Boston Shared contextBoston, Cambridge, and Brookline are ranked highly in sex toy purchases according to recent data.Moves Xenon
-
Virginia Shared contextAn agency relocated its office to downtown Richmond and operates within Virginia state.Moves Xenon
-
Nasdaq Shared contextGolub Capital BDC, Inc. listed on the electronic stock exchange.Moves Xenon
-
Chicago Shared contextA trader based in Chicago was involved in shorting Nvidia stock.Moves Xenon
Connections
The 14 strongest of 37, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Mortimer Structural
Mortimer serves as the President and CEO of Xenon.
-
Ian Mortimer Structural
Ian Mortimer serves as the President and CEO of Xenon Pharmaceuticals.
-
FDA Structural
FDA exercises formal regulatory oversight over Xenon's drug development and clinical trials, requiring submissions and approvals.
-
LinkedIn Operational
Xenon utilizes LinkedIn as a professional outreach and market presence platform.
-
Boston Shared context
Xenon operates and maintains a physical and media presence in Boston, receiving local grants and generating regional news coverage.
-
Virginia Shared context
Xenon presented its results at a conference held in Virginia.
-
Athens Shared context
Xenon presented Phase 3 data at a conference held in Athens.
-
Needham Mentioned together
Needham cut its price target for Xenon due to safety concerns.
Show all 14 connections
-
Deutsche Bank Transactional
The relationship is evidenced by a stock downgrade of Deutsche Bank citing safety concerns.
-
Nasdaq Shared context
Xenon is a company that trades on the Nasdaq stock exchange.
-
Chicago Shared context
Xenon presented results at a conference held in Chicago.
-
Massachusetts Shared context
Xenon is mentioned as operating within the context of Massachusetts.
-
American Academy of Neurology Operational
Xenon presented its research results at a meeting hosted by the American Academy of Neurology.
-
Vancouver Shared context
Xenon is consistently reported as being based in or operating within the city of Vancouver, BC.
History
Events by the month they beganSeptember 2026
3 eventsJuly 2026
1 eventJune 2026
7 events- Xenon and Neurocrine Biosciences announced a partnership on August 12, 2025, allowing collaboration and milestone payments regarding Azetukalner, which is Xenon's lead pipeline candidate.
- Xenon reported financial results from Vancouver and Boston and named Mortimer as its President and CEO.
- Xenon Pharmaceuticals maintains offices in Vancouver and Boston.
- RBC maintained an Outperform rating on Xenon Pharmaceuticals, noting Azetukalner as its top medication candidate, while Trump-era tariffs benefit AI stocks.
- Xenon Pharmaceuticals appointed Darren Cline as Chief Commercial Officer on June 24, 2025.
- Xenon Pharmaceuticals is developing azetukalner for various conditions and has completed patient recruitment for the X-TOLE2 Phase 3 clinical trial.
- Xenon Pharmaceuticals was included in a broad-market index on June 28, 2025.